The impact of drug administration sequence in a triplet chemotherapy comprising cisplatin, docetaxel and gemcitabine in patients with advanced non-small cell lung cancer: A phase II study of the Okayama Lung Cancer Study Group (OLCSG)

Toshiyuki Kozuki,Haruhito Kamei,Atsuhiko Tada,Shingo Harita,Keitaro Matsuo,Masahiro Tabata,Katsuyuki Kiura,Hiroshi Ueoka,Shunkichi Hiraki,M. Tanimoto

The impact of drug administration sequence in a triplet chemotherapy comprising cisplatin, docetaxel and gemcitabine in patients with advanced non-small cell lung cancer: A phase II study of the Okayama Lung Cancer Study Group (OLCSG)

2004

Toshiyuki Kozuki
Haruhito Kamei
Atsuhiko Tada
Shingo Harita
Keitaro Matsuo
Masahiro Tabata
Katsuyuki Kiura
Hiroshi Ueoka
Shunkichi Hiraki
M. Tanimoto

7249 Background: We have previously conducted a phase II study of a triplet chemotherapy with administration sequence of gemcitabine (GEM), docetaxel (DCT) and cisplatin (CDDP) in patients with adv...

Keywords:

Drug
Cisplatin/Docetaxel
Phases of clinical research
Cell
Lung cancer
Chemotherapy
Gemcitabine
Oncology
Internal medicine
Medicine
Cisplatin
drug administration
triplet chemotherapy
in patient
Docetaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations